Peapack Gladstone Financial Corp decreased its stake in Danaher Corporation (NYSE:DHR) by 3.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,676 shares of the conglomerate’s stock after selling 1,625 shares during the period. Peapack Gladstone Financial Corp’s holdings in Danaher Corporation were worth $4,277,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of DHR. Waldron LP purchased a new stake in shares of Danaher Corporation in the first quarter worth about $320,000. Empire Life Investments Inc. boosted its holdings in Danaher Corporation by 2.3% in the first quarter. Empire Life Investments Inc. now owns 77,900 shares of the conglomerate’s stock valued at $6,662,000 after purchasing an additional 1,764 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Danaher Corporation by 44.7% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,214 shares of the conglomerate’s stock valued at $4,209,000 after purchasing an additional 15,201 shares during the last quarter. Ingalls & Snyder LLC purchased a new position in Danaher Corporation in the first quarter valued at about $301,000. Finally, Northwestern Mutual Investment Management Company LLC boosted its holdings in Danaher Corporation by 76.4% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 123,325 shares of the conglomerate’s stock valued at $10,548,000 after purchasing an additional 53,430 shares during the last quarter. 75.49% of the stock is owned by institutional investors.
DHR has been the subject of a number of analyst reports. Jefferies Group LLC reissued a “buy” rating and issued a $95.00 price target on shares of Danaher Corporation in a report on Friday, August 4th. Citigroup Inc. set a $96.00 price target on Danaher Corporation and gave the company a “buy” rating in a report on Friday, July 21st. Zacks Investment Research raised Danaher Corporation from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a report on Friday, July 28th. Cowen and Company reissued a “buy” rating and issued a $90.00 price target on shares of Danaher Corporation in a report on Wednesday, October 4th. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $88.00 price target on shares of Danaher Corporation in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Danaher Corporation presently has a consensus rating of “Buy” and a consensus target price of $93.31.
Shares of Danaher Corporation (DHR) opened at 92.27 on Wednesday. The stock’s 50 day moving average price is $87.81 and its 200-day moving average price is $84.56. The firm has a market capitalization of $64.10 billion, a PE ratio of 29.45 and a beta of 1.03. Danaher Corporation has a 12 month low of $76.27 and a 12 month high of $92.47.
Danaher Corporation (NYSE:DHR) last released its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher Corporation had a return on equity of 11.29% and a net margin of 13.36%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 earnings per share. On average, equities analysts anticipate that Danaher Corporation will post $3.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend was Thursday, September 28th. Danaher Corporation’s dividend payout ratio (DPR) is currently 16.52%.
In other news, insider William King sold 43,688 shares of Danaher Corporation stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $82.86, for a total value of $3,619,987.68. Following the completion of the transaction, the insider now owns 45,748 shares in the company, valued at $3,790,679.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert S. Lutz sold 11,189 shares of Danaher Corporation stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now owns 18,314 shares of the company’s stock, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. Insiders sold 153,639 shares of company stock valued at $13,632,773 in the last quarter. 12.20% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Peapack Gladstone Financial Corp Has $4.28 Million Stake in Danaher Corporation (DHR)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/11/01/peapack-gladstone-financial-corp-has-4-28-million-stake-in-danaher-corporation-dhr.html.
Danaher Corporation Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
What are top analysts saying about Danaher Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Danaher Corporation and related companies.